What does CUSIP 98420X202 represent in this 13F holders report?

CUSIP 98420X202 is the security identifier for XFOR - X4 Pharmaceuticals, Inc - Common Stock used to aggregate holder disclosures.

How many institutions held XFOR - X4 Pharmaceuticals, Inc - Common Stock in Q4 2025?

75 institutional investors reported XFOR - X4 Pharmaceuticals, Inc - Common Stock for Q4 2025. Use the holders table for investor-level position and value details.

X4 Pharmaceuticals, Inc - Common Stock (XFOR)

CUSIP: 98420X202

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock
Shares outstanding: 87,101,353
Total 13F shares: 85,919,846
Share change: +57,015,275
Total reported value: $343,681,474
Price per share: $4.00
Number of holders: 75
Value change: +$228,817,038
Number of buys: 53
Number of sells: 11

Quarterly Holders Quick Answers

What is CUSIP 98420X202?
CUSIP 98420X202 identifies XFOR - X4 Pharmaceuticals, Inc - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 98420X202:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Top shareholders of XFOR - X4 Pharmaceuticals, Inc - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Empery Asset Management, LP	13D/G	—	10%	9,043,894	$35,180,748	+$25,462,897	31 Dec 2025	13D/G
FMR LLC	13D/G	—	9.7%	8,499,100	$33,996,400	$0	31 Oct 2025	13D/G
Saturn V Capital Management LP	13D/G	—	7.4%	6,433,481	$25,026,241	$0	24 Oct 2025	13D/G
PERCEPTIVE ADVISORS LLC	13D/G	—	7.6%	6,064,680	$20,980,760	$0	27 Oct 2025	13D/G
Trails Edge Capital Partners, LP	13D/G	—	5.8%	5,227,222	$20,333,894	+$11,320,168	31 Dec 2025	13D/G
Growth Equity Opportunities 18 VGE, LLC	13D/G	—	6.2%	5,057,610	$17,496,802	+$9,734,867	27 Oct 2025	13D/G
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	3.9%	3,411,993	$13,272,653	+$4,544,819	31 Dec 2025	13D/G
Nantahala Capital Management, LLC	13D/G 13F	Company	2.8%	2,449,468	$9,528,431	+$798,030	31 Dec 2025	13D/G 13F
Bain Capital Life Sciences Investors, LLC	13F	Company	2.8%	2,436,588	$8,333,131	—	30 Sep 2025	13F
Coastlands Capital LP	13D/G	—	10%	2,491,638	$7,773,911	+$37,418	03 Oct 2025	13D/G
NEA Management Company, LLC	13F	Company	28%	2,233,743	$7,639,401	—	30 Sep 2025	13F
BVF INC/IL	13F	Company	2.6%	2,233,742	$7,639,398	—	30 Sep 2025	13F
Rosalind Advisors, Inc.	13F	Company	1.8%	1,544,607	$5,282,555	—	30 Sep 2025	13F
Deep Track Capital, LP	13D/G 13F	Company	10%	2,366,995	$4,568,300	$0	12 Aug 2025	13D/G 13F
Stonepine Capital Management, LLC	13F	Company	1.2%	1,056,338	$3,612,676	—	30 Sep 2025	13F
KINGDON CAPITAL MANAGEMENT, L.L.C.	13F	Company	1.1%	933,332	$3,191,995	—	30 Sep 2025	13F
STEMPOINT CAPITAL LP	13F	Company	0.64%	555,411	$1,899,506	—	30 Sep 2025	13F
VANGUARD GROUP INC	13D/G 13F	The Vanguard Group · Company	4.8%	8,200,903	$1,558,172	$0	31 Dec 2024	13D/G 13F
Paula Ragan	3/4/5	President and CEO, Director	— mixed-class rows	4,526,964 mixed-class rows	$1,515,173	—	12 Feb 2025	3/4/5
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.39%	343,963	$1,176,353	—	30 Sep 2025	13F
Adam R. Craig	3/4/5	Executive Chairman, Director	— mixed-class rows	2,705,241 mixed-class rows	$1,090,652	+$249,997	29 Oct 2025	3/4/5
ACORN CAPITAL ADVISORS, LLC	13F	Company	3.4%	273,349	$934,855	—	30 Sep 2025	13F
Pale Fire Capital SE	13F	Company	0.21%	180,851	$618,510	—	30 Sep 2025	13F
John Volpone	3/4/5	President	— mixed-class rows	2,619,035 mixed-class rows	$550,773	—	29 Oct 2025	3/4/5
UBS Group AG	13F	Company	0.18%	159,835	$546,635	—	30 Sep 2025	13F
Mary DiBiase	3/4/5	Chief Operating Officer	— mixed-class rows	1,569,228 mixed-class rows	$518,005	—	12 Feb 2025	3/4/5
Christophe Arbet-Engels	3/4/5	Chief Medical Officer	— mixed-class rows	1,045,023 mixed-class rows	$392,350	—	12 Feb 2025	3/4/5
Adam S. Mostafa	3/4/5	Chief Financial Officer	— mixed-class rows	1,373,414 mixed-class rows	$385,900	—	12 Feb 2025	3/4/5
BlackRock, Inc.	13D/G 13F	Company	3%	179,125	$377,954	$0	30 Jun 2025	13D/G 13F
David Kirske	3/4/5	Chief Financial Officer	— mixed-class rows	1,746,023 mixed-class rows	$367,182	—	29 Oct 2025	3/4/5
Palumbo Wealth Management LLC	13F	Company	0.11%	95,327	$326,019	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.09%	79,658	$272,472	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.07%	64,795	$221,599	—	30 Sep 2025	13F
Arthur Taveras	3/4/5	Chief Scientific Officer	— mixed-class rows	816,274 mixed-class rows	$218,459	—	04 Oct 2024	3/4/5
STATE STREET CORP	13F	Company	0.04%	38,734	$132,470	—	30 Sep 2025	13F
Derek M. Meisner	3/4/5	Chief Legal Officer	— class O/S missing	145,155	$130,640	—	17 Aug 2022	3/4/5
Diego Cadavid	3/4/5	Chief Medical Officer	— class O/S missing	104,107	$93,696	—	01 Mar 2022	3/4/5
Alison Frances Lawton	3/4/5	Director	— class O/S missing	96,667	$85,241	—	10 Jun 2024	3/4/5
William Aliski	3/4/5	Director	— class O/S missing	96,667	$85,241	—	10 Jun 2024	3/4/5
Point72 Asset Management, L.P.	13F	Company	0.02%	21,666	$74,098	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.02%	19,304	$66,020	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.02%	19,177	$65,585	—	30 Sep 2025	13F
Mark Baldry	3/4/5	Chief Commercial Officer	0.32%	25,337	$62,886	—	16 May 2025	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.02%	13,868	$47,429	—	30 Sep 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	10,679	$36,522	—	30 Sep 2025	13F
ORBIMED ADVISORS LLC	13D/G	—	1.7%	134,947	$25,640	$0	30 Jun 2025	13D/G
GROUP ONE TRADING LLC	13F	Company	0%	3,998	$13,673	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0%	3,728	$12,750	—	30 Sep 2025	13F
Point72 Asia (Singapore) Pte. Ltd.	13F	Company	0%	2,914	$9,966	—	30 Sep 2025	13F
ROYAL BANK OF CANADA	13F	Company	0%	2,525	$9,000	—	30 Sep 2025	13F

Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) as of Q4 2025

As of 31 Dec 2025, X4 Pharmaceuticals, Inc - Common Stock (XFOR) was held by 75 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 85,919,846 shares. The largest 10 holders included Empery Asset Management, LP, FMR LLC, MORGAN STANLEY, Bain Capital Life Sciences Investors, LLC, PERCEPTIVE ADVISORS LLC, Saturn V Capital Management LP, Deep Track Capital, LP, Kalehua Capital Management LLC, VANGUARD GROUP INC, and BRAIDWELL LP. This page lists 75 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.